Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
NASDAQ:ITRM
Price:
1.67 USD
6.37%
Market Closed
Updated:
Apr 27, 2024
Iterum Therapeutics PLC
Cash from Financing Activities
|
Iterum Therapeutics PLC
Cash from Financing Activities Peer Comparison
Comparables:
PRGO
JAZZ
AVDL
G
GHRS
COPN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Cash from Financing Activities
$1m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Cash from Financing Activities
-$187.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Cash from Financing Activities
-$305.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
-29%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Cash from Financing Activities
$135.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
22%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Cash from Financing Activities
-$204k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Cash from Financing Activities
-€209.3m
|
CAGR 3-Years
-160%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Iterum Therapeutics PLC's Cash from Financing Activities?
Cash from Financing Activities
1m
USD
1m
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Cash from Financing Activities amounts to 1m USD.
What is Iterum Therapeutics PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-61%
-61%
The average annual Cash from Financing Activities growth rates for Iterum Therapeutics PLC have been -75% over the past three years , -61% over the past five years .
You don't have any saved screeners yet
